|
1
|
Saltos A, Shafique M and Chiappori A:
Update on the biology, management, and treatment of small cell lung
cancer (SCLC). Front Oncol. 10(1074)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rous FA, Singhi EK, Sridhar A, Faisal MS
and Desai A: Lung cancer treatment advances in 2022. Cancer Invest.
41:12–24. 2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yang S, Zhang Z and Wang Q: Emerging
therapies for small cell lung cancer. J Hematol Oncol.
12(47)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Curigliano G, Cardinale D, Suter T,
Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch
A, Cipolla C and Roila F: ESMO Guidelines Working Group.
Cardiovascular toxicity induced by chemotherapy, targeted agents
and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 23
(Suppl 7):vii155–vii166. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lyon AR, Dent S, Stanway S, Earl H,
Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke
JD, Bergler-Klein J, et al: Baseline cardiovascular risk assessment
in cancer patients scheduled to receive cardiotoxic cancer
therapies: A position statement and new risk assessment tools from
the Cardio-Oncology Study Group of the Heart failure association of
the European Society of cardiology in collaboration with the
international cardio-oncology society. Eur J Heart Fail.
22:1945–1960. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu
YL, Liu LF and Yeh ET: Identification of the molecular basis of
doxorubicin-induced cardiotoxicity. Nat Med. 18:1639–1642.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Herrmann J, Lerman A, Sandhu NP,
Villarraga HR, Mulvagh SL and Kohli M: Evaluation and management of
patients with heart disease and cancer: Cardio-oncology. Mayo Clin
Proc. 89:1287–1306. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Liang H, Wang T, Liu D, Wang H, Ba Z, Xiao
Y, Liu Y, Yuan J and Yang W: Cardiovascular comorbidities and their
prognostic value in small cell lung cancer patients with
chemoradiotherapy. Clin Transl Oncol. 26:1348–1356. 2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Minotti G, Menna P, Salvatorelli E, Cairo
G and Gianni L: Anthracyclines: Molecular advances and
pharmacologic developments in antitumor activity and
cardiotoxicity. Pharmacol Rev. 56:185–229. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Cardinale D, Colombo A, Torrisi R, Sandri
MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S,
Dessanai MA, et al: Trastuzumab-induced cardiotoxicity: Clinical
and prognostic implications of troponin I evaluation. J Clin Oncol.
28:3910–3916. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sawaya H, Sebag IA, Plana JC, Januzzi JL,
Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, et al:
Early detection and prediction of cardiotoxicity in
chemotherapy-treated patients. Am J Cardiol. 107:1375–1380.
2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Maisel A, Mueller C, Adams K Jr, Anker SD,
Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di
Somma S, et al: State of the art: Using natriuretic peptide levels
in clinical practice. Eur J Heart Fail. 10:824–839. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Neilan TG, Coelho-Filho OR, Shah RV, Feng
JH, Pena-Herrera D, Mandry D, Pierre-Mongeon F, Heydari B, Francis
SA, Moslehi J, et al: Myocardial extracellular volume by cardiac
magnetic resonance imaging in patients treated with
anthracycline-based chemotherapy. Am J Cardiol. 111:717–722.
2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yu AF and Ky B: Roadmap for biomarkers of
cancer therapy cardiotoxicity. Heart. 102:425–430. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Cartas-Espinel I, Telechea-Fernández M,
Delgado CM, Barrera AA, Cuevas NS and Riffo-Campos AL: Novel
molecular biomarkers of cancer therapy-induced cardiotoxicity in
adult population: A scoping review. ESC Heart Fail. 9:1651–1665.
2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ganti AKP, Loo BW, Bassetti M, Blakely C,
Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M,
et al: Small cell lung cancer, version 2.2022, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
19:1441–1464. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Vallières E, Shepherd FA, Crowley J, Van
Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw
P: International Association for the Study of Lung Cancer
International Staging Committee and Participating Institutions. The
IASLC lung cancer staging project: Proposals regarding the
relevance of TNM in the pathologic staging of small cell lung
cancer in the forthcoming (seventh) edition of the TNM
classification for lung cancer. J Thorac Oncol. 4:1049–1059.
2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhang S, Liang F and Tannock I: Use and
misuse of common terminology criteria for adverse events in cancer
clinical trials. BMC Cancer. 16(392)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
a19. R Core Team (2021). R: A language and
environment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. URL https://www.R-project.org/.
|
|
20
|
Chan SHY, Khatib Y, Webley S, Layton D and
Salek S: Identification of cardiotoxicity related to non-small cell
lung cancer (NSCLC) treatments: A systematic review. Front
Pharmacol. 14(1137983)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cardinale D, Sandri MT, Colombo A, Colombo
N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G,
Fiorentini C and Cipolla CM: Prognostic value of troponin I in
cardiac risk stratification of cancer patients undergoing high-dose
chemotherapy. Circulation. 109:2749–2754. 2004.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gevaert AB, Kataria R, Zannad F, Sauer AJ,
Damman K, Sharma K, Shah SJ and Van Spall HGC: Heart failure with
preserved ejection fraction: Recent concepts in diagnosis,
mechanisms and management. Heart. 108:1342–1350. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Reding KW, O'Connell NS, D'Agostino RB Jr,
Hundley W, Lucas AR, Ladd AC, Jordan JH, Heiston EM, Ge Y and
Hundley WG: Both intermuscular fat and LVEF decline promote heart
failure symptoms in cancer survivors. Cardiooncology.
7(16)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gupta V, Singh SK, Agrawal V and Singh TB:
Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A
randomized, double-blind, placebo-controlled trial. Pediatr Blood
Cancer. 65(e27308)2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Rydzek J, Gąsior ZT, Dąbek J, Wojnar J and
Skrzypek M: Assessment of risk factors for mortality in patients
with cardiovascular disease and a history of treatment for
malignancy. Kardiol Pol. 73:730–739. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Katsioupa M, Kourampi I, Oikonomou E,
Tsigkou V, Theofilis P, Charalambous G, Marinos G, Gialamas I,
Zisimos K, Anastasiou A, et al: Novel biomarkers and their role in
the diagnosis and prognosis of acute coronary syndrome. Life
(Basel). 13(1992)2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chen D, Xu J, Qiao R, Zhao Y, Chu T, Han B
and Zhong R: Detection of genetic mutations by next-generation
sequencing for predicting prognosis of extensive-stage small-cell
lung cancer. J Oncol. 2020(8811487)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Linschoten M, Teske AJ, Baas AF, Vink A,
Dooijes D, Baars HF and Asselbergs FW: Truncating Titin (TTN)
variants in chemotherapy-induced cardiomyopathy. J Card Fail.
23:476–479. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tham YK, Bernardo BC, Ooi JY, Weeks KL and
McMullen JR: Pathophysiology of cardiac hypertrophy and heart
failure: Signaling pathways and novel therapeutic targets. Arch
Toxicol. 89:1401–1438. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Öztürk C, Validyev D, Becher UM, Weber M,
Nickenig G and Tiyerili V: A novel scoring system to estimate
chemotherapy-induced myocardial toxicity: Risk assessment prior to
non-anthracycline chemotherapy regimens. Int J Cardiol Heart Vasc.
33(100751)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Savarese G, Stolfo D, Sinagra G and Lund
LH: Heart failure with mid-range or mildly reduced ejection
fraction. Nat Rev Cardiol. 19:100–116. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Salem SS, Saleh NY, Soliman SE and
Abo-Haded HM: On-admission plasma levels of BNP, MR-proADM, and
cTnI in pediatric heart failure: Contributions to diagnosis,
prognosis, and outcome. Ir J Med Sci. 191:263–270. 2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Gürgöze MT, van Vark LC, Baart SJ, Kardys
I, Akkerhuis KM, Manintveld OC, Postmus D, Hillege HL,
Lesman-Leegte I, Asselbergs FW, et al: Multimarker analysis of
serially measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, creatinine,
and prognosis in acute heart failure. Circ Heart Fail.
16(e009526)2023.PubMed/NCBI View Article : Google Scholar
|
